BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 28.04 Million EUR | 47.69% |
| 2022 | 18.98 Million EUR | 68.21% |
| 2021 | 11.28 Million EUR | 7475.84% |
| 2020 | 149 Thousand EUR | -97.07% |
| 2019 | 5.08 Million EUR | 8.61% |
| 2018 | 4.67 Million EUR | 37.95% |
| 2017 | 3.39 Million EUR | 142.97% |
| 2016 | -7.89 Million EUR | 62.74% |
| 2015 | -21.17 Million EUR | -387.47% |
| 2014 | 7.36 Million EUR | 136.05% |
| 2013 | 3.12 Million EUR | 706.02% |
| 2012 | -515 Thousand EUR | 77.77% |
| 2011 | -2.31 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 24.86 Million EUR | -11.33% |
| 2024 Q2 | 24.86 Million EUR | 4.47% |
| 2023 Q4 | 28.04 Million EUR | 0.0% |
| 2023 Q3 | 28.04 Million EUR | 14.39% |
| 2023 FY | 28.04 Million EUR | 47.69% |
| 2023 Q1 | 24.22 Million EUR | 27.58% |
| 2023 Q2 | 24.51 Million EUR | 1.21% |
| 2022 Q4 | 18.98 Million EUR | -13.48% |
| 2022 FY | 18.98 Million EUR | 68.21% |
| 2022 Q2 | 15.94 Million EUR | 0.0% |
| 2022 Q3 | 21.94 Million EUR | 37.68% |
| 2021 Q2 | 6.53 Million EUR | 0.0% |
| 2021 Q4 | 11.28 Million EUR | 0.0% |
| 2021 FY | 11.28 Million EUR | 7475.84% |
| 2020 FY | 149 Thousand EUR | -97.07% |
| 2020 Q4 | 149 Thousand EUR | 0.0% |
| 2020 Q2 | 11.89 Million EUR | 0.0% |
| 2019 Q4 | 5.08 Million EUR | 0.0% |
| 2019 Q2 | 2.84 Million EUR | 0.0% |
| 2019 FY | 5.08 Million EUR | 8.61% |
| 2018 Q2 | 4.25 Million EUR | 0.0% |
| 2018 FY | 4.67 Million EUR | 37.95% |
| 2018 Q4 | 4.67 Million EUR | 0.0% |
| 2017 Q4 | 3.39 Million EUR | 0.0% |
| 2017 FY | 3.39 Million EUR | 142.97% |
| 2017 Q2 | -851 Thousand EUR | 0.0% |
| 2016 Q2 | -13.7 Million EUR | 0.0% |
| 2016 Q4 | -7.89 Million EUR | 0.0% |
| 2016 FY | -7.89 Million EUR | 62.74% |
| 2015 Q2 | -27.71 Million EUR | 0.0% |
| 2015 Q4 | -21.17 Million EUR | 0.0% |
| 2015 FY | -21.17 Million EUR | -387.47% |
| 2014 Q4 | 7.36 Million EUR | 10.17% |
| 2014 Q3 | 6.68 Million EUR | 0.0% |
| 2014 FY | 7.36 Million EUR | 136.05% |
| 2013 FY | 3.12 Million EUR | 706.02% |
| 2013 Q4 | 3.12 Million EUR | 0.0% |
| 2012 FY | -515 Thousand EUR | 77.77% |
| 2011 FY | -2.31 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 4027.731% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 114.273% |
| Adocia SA | 127 Thousand EUR | -21981.89% |
| Aelis Farma SA | -16.19 Million EUR | 273.197% |
| Biophytis S.A. | 2.7 Million EUR | -937.514% |
| Advicenne S.A. | 12.17 Million EUR | -130.341% |
| genOway Société anonyme | 2.97 Million EUR | -843.299% |
| IntegraGen SA | -709.74 Thousand EUR | 4051.256% |
| Medesis Pharma S.A. | 1.15 Million EUR | -2321.323% |
| Neovacs S.A. | -237.08 Thousand EUR | 11928.569% |
| NFL Biosciences SA | -2.27 Million EUR | 1332.232% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -543.726% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 3476.566% |
| Sensorion SA | 1.37 Million EUR | -1934.796% |
| Theranexus Société Anonyme | 2.44 Million EUR | -1047.39% |
| TME Pharma N.V. | -1.07 Million EUR | 2699.073% |
| Valbiotis SA | -18.13 Million EUR | 254.606% |
| TheraVet SA | 12.78 Thousand EUR | -219250.802% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -1186.422% |
| argenx SE | -1.83 Billion EUR | 101.527% |
| Celyad Oncology SA | -6.1 Million EUR | 559.587% |
| DBV Technologies S.A. | -114.95 Million USD | 124.395% |
| Galapagos NV | -157.2 Million EUR | 117.839% |
| Genfit S.A. | -7.61 Million EUR | 468.467% |
| GeNeuro SA | 5.91 Million EUR | -374.486% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 211.676% |
| Innate Pharma S.A. | -30.71 Million EUR | 191.313% |
| Inventiva S.A. | 10.48 Million EUR | -167.366% |
| MaaT Pharma SA | -10.2 Million EUR | 374.806% |
| MedinCell S.A. | 39.5 Million EUR | 29.004% |
| Nanobiotix S.A. | -24.71 Million EUR | 213.456% |
| Onward Medical N.V. | -12.89 Million EUR | 317.497% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -1860.661% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -3.373% |
| Oxurion NV | 10.71 Million EUR | -161.849% |
| Pharming Group N.V. | 99.4 Million EUR | 71.787% |
| Poxel S.A. | 44.55 Million EUR | 37.063% |
| GenSight Biologics S.A. | 16.29 Million EUR | -72.112% |
| Transgene SA | -14.4 Million EUR | 294.628% |
| Financière de Tubize SA | 78.62 Million EUR | 64.332% |
| UCB SA | 2.17 Billion EUR | 98.712% |
| Valneva SE | 82.73 Million EUR | 66.104% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 251.393% |